Detalhe da pesquisa
1.
Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
Gynecol Oncol
; 155(2): 331-339, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31493899
2.
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
BMC Cancer
; 14: 179, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24625059
3.
Claudin-18 overexpression in intestinal-type mucinous borderline tumour of the ovary.
Histopathology
; 63(4): 534-44, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23905715
4.
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.
Oncotarget
; 7(46): 75328-75338, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27659536
5.
Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
PLoS One
; 10(6): e0128066, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26043110
6.
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
PLoS One
; 9(2): e87220, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24504419
7.
Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer.
Oncol Rep
; 30(2): 584-8, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23733133
8.
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
PLoS One
; 7(5): e37431, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22662154
9.
Correction: Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas.
PLoS One
; 10(7): e0132751, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26147301